Tetraphase Pharmaceuticals Price Target Increased to $16.00 by Analysts at JMP Securities (TTPH)
Investment analysts at JMP Securities raised their price objective on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from $12.00 to $16.00 in a note issued to investors on Tuesday, AnalystRatings.Net reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price objective would suggest a potential upside of 35.94% from the company’s current price.
TTPH has been the subject of a number of other recent research reports. Analysts at Needham & Company reiterated a “buy” rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note to investors on Tuesday. They now have a $15.00 price target on the stock, up previously from $12.00. Separately, analysts at WBB Securities initiated coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note to investors on Monday. They set a “speculative buy” rating on the stock. Finally, analysts at Ladenburg Thalmann initiated coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note to investors on Wednesday, August 21st. They set a “buy” rating and a $13.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, Tetraphase Pharmaceuticals has a consensus rating of “Buy” and an average target price of $15.20.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 3.43% on Tuesday, hitting $11.77. The stock had a trading volume of 164,259 shares. Tetraphase Pharmaceuticals has a 52 week low of $7.00 and a 52 week high of $11.77. The stock’s 50-day moving average is $9.56 and its 200-day moving average is $8.27. The company’s market cap is $243.3 million.
In other Tetraphase Pharmaceuticals news, major shareholder Ventures Vi Lp Cmea sold 100,000 shares of the stock on the open market in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $10.20, for a total transaction of $1,020,000.00. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.